Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aarhus University
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Oct 15, 2024
Emerging Company Profile
Commit: Activating the complement pathway to deeply deplete target cells
Launched in May, Danish company’s tech engages C1q to trigger complement-induced killing of cancer or autoimmune cells
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Feb 28, 2024
Emerging Company Profile
Vesper Bio: a sortilin-targeting pill to treat neurological disease
Lundbeckfonden-backed start-up believes at-home oral therapy would offer benefits over injectables for genetically defined patients with dementia
BioCentury | Mar 15, 2023
Finance
March 14 Quick Takes: Switch launches with $52M and conditional gene knockdown tech
Plus: Servier’s vorasidenib meets glioma endpoint and updates from Teitur, AlgoTx, GSK, Acesion, Sophia Genetics and more
BioCentury | Feb 2, 2023
Emerging Company Profile
PrecisionLife: learning from genetic interactions by cutting noise
U.K. company untangling genomic interactions to find targets in complex diseases
BioCentury | Jun 9, 2022
Management Tracks
Goldstein becomes president and CMO at Aurion
Plus Duke to be CFO at Apexigen and updates from MC2, Pillar, Nonagen and more
BioCentury | Apr 7, 2022
Data Byte
A Distillery snapshot of Danish innovation
Discoveries include a TB vaccine and a brain metabolite analog for stroke
BioCentury | Feb 23, 2022
Finance
Jeito joins NMD’s syndicate to help Danish play build clinical, U.S. strategy
The French VC attracted by NMD’s ability to identify patients with severe neuromuscular disease likely to respond to therapy
BioCentury | Feb 9, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into infectious disease
Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
Items per page:
1 - 10 of 41